AUS
NZ
UK
CA
USA
IND
Highlights
Mid-cap growth names Raspberry Pi and Oxford Instruments were notable fallers as risk appetite drained from the London market.
The AI-infrastructure theme stayed prominent after London Tech Week, keeping names such as IQE, Computacenter and Segro in focus.
AstraZeneca digested a regulatory timeline extension for camizestrant, a reminder that growth stories carry milestone risk as well as promise.
Growth investing is a fair-weather sport on days like this. With the FTSE 100 and FTSE 250 drifting near multi-week lows on Middle East tension, a fragile ceasefire and pre-positioning ahead of a key US inflation reading, the market's appetite for richly valued, expectation-laden shares thinned noticeably. The result was a session in which some of London's most celebrated growth stories gave ground, even as the structural themes powering them, above all artificial intelligence infrastructure, remained very much intact. For followers of the UK growth cohort, it was a day that separated the narrative from the noise.
The mechanics are familiar. Growth shares derive much of their worth from profits expected far in the future, which makes them acutely sensitive to shifts in rate expectations and risk sentiment. When geopolitics flares and an inflation print looms, traders trim the positions with the most embedded optimism first. That is rarely a judgement on any individual company; it is simply how nervous markets behave. The interesting question is always which names get swept up indiscriminately and which are repricing on genuine news.
Why did Raspberry Pi and Oxford Instruments fall?
Two of the mid-cap market's best-known growth names bore the brunt of the cautious mood. Raspberry Pi (LSE:RPI), the single-board computer maker that has become one of the most-watched listings on the London market, was a notable faller after a run of remarkable strength that has made it a flagship of the UK's homegrown technology ambitions. Oxford Instruments (LSE:OXIG), the precision-instruments group whose tools serve quantum computing, semiconductor and life-science research, also slipped sharply. In both cases the moves looked more like a reassessment of stretched expectations in a risk-off tape than a verdict on the underlying franchises. Companies whose shares have climbed steeply leave little room for disappointment, and on nervous days that thin margin for error is exactly where sellers concentrate. The episode is a reminder that volatility is the toll growth investors pay for participation in compounding stories.
Did the AI-infrastructure trade hold up?
If the session had a resilient corner, it was the cluster of names tied to artificial intelligence infrastructure. The afterglow of London Tech Week, which showcased major commitments to British computing capacity, supercomputing projects and sovereign AI capabilities, has kept a spotlight on the companies positioned along that build-out. Compound semiconductor specialist IQE (AIM:IQE) has been one of the year's most dramatic gainers as investors connect its wafer technology to data-centre and sensing demand. IT-infrastructure services group Computacenter (LSE:CCC) sits directly in the path of corporate AI deployment budgets, while warehouse and data-centre landlord Segro (LSE:SGRO) offers a property-market expression of the same theme. Software and analytics names RELX (LSE:REL) and Sage (LSE:SGE) continue to be discussed as monetisers of AI within existing customer bases, and BT Group (LSE:BT.A) features in conversations about the network backbone the technology will require. The theme's breadth is its strength: it no longer rests on a single stock or sector.
What did AstraZeneca's regulatory news signal?
Growth is not only a technology story on the London market. AstraZeneca (LSE:AZN), the index's pharmaceutical heavyweight and one of its core growth franchises, absorbed news that US regulators had extended the decision timeline for camizestrant, an oncology candidate viewed as an important piece of its next wave of medicines. Timeline extensions are common in drug development and do not in themselves change a molecule's prospects, but they illustrate a truth that applies across the growth cohort: these are milestone-driven investments, and the calendar can move against holders even when the science does not. For a company with a pipeline as broad as AstraZeneca's, single-program delays matter less than the portfolio's overall cadence, which is exactly why the market's reaction tends to be measured rather than dramatic.
Growth stocks in the UK are concentrated in the technology, healthcare, industrial-technology and consumer-discretionary sectors of the FTSE 350, with a further deep bench on the Alternative Investment Market. Under the Industry Classification Benchmark, they include software and computer services groups such as Sage and Computacenter, semiconductor and electronics businesses such as IQE and Raspberry Pi, scientific-instrument makers such as Oxford Instruments, pharmaceutical innovators led by AstraZeneca, and data and analytics groups such as RELX. The defining traits are expanding addressable markets, reinvestment of cash flow into product development, and valuations that reflect anticipated rather than purely historical earnings, which is why the cohort is more sensitive than the wider market to changes in interest-rate expectations.
How should observers read a day like this?
Sessions dominated by geopolitics rarely change the trajectory of structural themes, but they do reveal positioning. The fact that the sharpest falls landed on the names with the steepest recent gains suggests profit-taking rather than thesis change, while the relative resilience of the broader AI-infrastructure cluster points to a theme that investors are reluctant to abandon even in a risk-off tape. The next catalysts are clear enough: the US inflation reading will shape the rate backdrop that governs growth-stock valuations, the durability of the Middle East ceasefire will set overall risk appetite, and company-level updates will determine which of London's growth stories keep earning their premium ratings. Days like this one are uncomfortable for holders, but they are also when the distinction between durable franchises and borrowed momentum becomes easiest to see.
